ABSTRACT: Intravenous pamidronate is widely used to treat children with moderate to severe osteogenesis imperfecta (OI). Changes in the appearance of osteoclasts have previously been noted in children receiving pamidronate and have been interpreted as signs of toxicity. In this study, we analyzed osteoclast parameters in paired iliac bone specimens before and after 2-4 yr of cyclical intravenous pamidronate therapy in 44 pediatric OI patients (age range: 1.4-17.5 yr; 21 girls). During pamidronate treatment, average osteoclast diameter and the mean number of nuclei present per osteoclast increased by 18% (p = 0.02) and 43% (p < 0.001), respectively. The number of samples containing large osteoclasts (LOcs, diameter > 50 mm) increased from 6 (14%) before treatment to 23 (52%) after pamidronate therapy (p < 0.001 by x 2 test). Post-treatment samples containing LOcs had a greater core width (p = 0.04) and a higher cancellous bone volume per tissue volume (p < 0.001), because cancellous bone volume had increased more during pamidronate treatment (p < 0.001). Osteoclast number and surface were higher in samples with LOcs, but there was no difference in cancellous bone formation parameters. The presence of LOcs was independent of OI type, type of collagen type I mutation, lumbar spine BMD, and other clinical or biochemical measures. In conclusion, this study did not show any indication that LOcs during pamidronate treatment are indicative of toxicity. It seems more likely that the observed abnormalities in osteoclast morphology are part of the mechanism of action of this drug.
INTRODUCTION
O STEOGENESIS IMPERFECTA (OI) is a genetic disorder with increased bone fragility and low bone mass. (1) In the majority of patients with OI, the disease is inherited in an autosomal dominant manner and can be linked to mutations in one of the two genes encoding collagen type I a chains (COL1A1 and COL1A2). The clinical severity of the syndrome varies from death in utero to absence of symptoms.
Pamidronate is now used worldwide to treat children and adolescents with moderate to severe forms of OI.
(1) This treatment has been reported to increase lumbar spine BMD and metacarpal cortical width, to decrease fracture rate, and to improve mobility. (1) (2) (3) Pamidronate is a nitrogencontaining bisphosphonate that interferes with the mevalonate pathway in osteoclasts. (4) This indirectly leads to the loss of function of small GTPases. These are signaling proteins that are involved a variety of cell processes important for osteoclast function, including cell morphology, cytoskeletal arrangement, membrane ruffling, trafficking of vesicles, and apoptosis. Even though all bisphosphonates were initially believed to exert their antiresorptive activity mainly though osteoclast apoptosis, it is now clear that nitrogen-containing bisphosphonates such as pamidronate inhibit bone resorption mostly through interference with the osteoclast cytoskeleton rather than apoptosis. (5) It was reported >30 yr ago that, after bisphosphonate administration in growing rats, osteoclasts change in morphology, have an increased number of nuclei, and appear inactive. (6, 7) In accordance with these animal studies, we have previously reported that iliac bone samples of OI patients who had received pamidronate often contain unusually large osteoclasts (LOcs). (8) It has been subsequently hypothesized that LOcs represent ''sick osteoclasts,'' which are a sign of pamidronate toxicity and may be associated with clinical complications. (9) However, it is not clear at present whether these abnormalities in osteoclast appearance are actually indicative of toxicity or rather are part of the expected anti-osteoclast activity of bisphosphonates.
Given the uncertainty surrounding the clinical significance of abnormal osteoclast morphology during pamidronate treatment, we assessed whether the presence of LOcs is associated with signs of undesired effects in young OI patients receiving pamidronate.
MATERIALS AND METHODS

Subjects
This study comprised patients with a diagnosis of OI type I, III, or IV who received pamidronate therapy at the Shriners Hospital for Children in Montreal. Patients were eligible for pamidronate treatment if they had long-bone deformities or had suffered more than two fractures per year during the previous 2 yr. The study was approved by the Shriners Hospital Institutional Review Board, and informed consent was obtained from legal guardians.
According to the treatment protocol, iliac bone biopsy specimens were obtained before treatment and after at least 2 yr of therapy. These specimens were preferentially taken during times of elective orthopedic operations. However, if the patient did not require any surgical interventions, bone samples were obtained in a procedure performed exclusively for this purpose.
Paired bone specimens from 44 patients (21 girls, 23 boys; age range: 1.4-17.5 yr) were included in the study. The diagnostic distribution of OI types was as follows: OI type I, n = 11; OI type III, n = 10; OI type IV, n = 23. Collagen type I mutations were found in 39 of these patients. In three patients, no collagen type I mutation was detectable by sequence analysis of the coding regions of the COL1A1 and COL1A2 genes, but a diagnosis of OI was made on the basis of typical clinical findings (dentinogenesis imperfecta, blue sclera). Two patients had not undergone genetic testing.
Pamidronate was administered in 3-day infusion cycles that were repeated every 2-4 mo dependent on age, as described previously.
(1) The total annual dose for all patients regardless of age was 9 mg/kg body weight. All patients received supplemental calcium and vitamin D according to the recommended daily allowance for age. Patients were involved in regular physiotherapy, occupational therapy, and medical and surgical evaluation as part of the multidisciplinary care for these children.
Bone biopsy and histomorphometry
Bone biopsies were performed before the start of pamidronate treatment and after 2-4 yr of therapy. The sample that was obtained during treatment was usually taken when the patient returned for the next pamidronate treatment. Therefore, the samples were obtained 4 mo after the previous pamidronate infusion. Full-thickness transiliac bone biopsy samples were obtained with a Bordier trephine (5 or 6 mm core diameter) under general anesthesia from a site located 2 cm behind the anterior superior iliac spine. It was attempted to collect the specimen on days 4-5 after dual labeling with demeclocycline (at a daily dose of 15-20 mg/kg body weight taken orally during two 2-day periods separated by a 10-day free interval). However, eight patients underwent their second biopsy procedure during orthopedic interventions that were scheduled on short notice so that it was not possible to perform the labeling course. Consequently, dynamic measures of bone formation could not be evaluated in the samples from these patients.
Biopsy preparation and histomorphometric analyses were performed as previously described. (10) Two pretreatment samples and one specimen obtained during treatment were slightly crushed and therefore had to be excluded from the analysis of core width. Osteoclast diameter was measured as the shortest diameter through the center of an osteoclast.
Osteoclasts were denoted as large when their diameter exceeded 50 mm. This cut-off value represents the upper end of the range in osteoclast diameter that we observed in iliac bone samples from children without metabolic bone disease. (10) Three of the pretreatment bone samples and one sample obtained during pamidronate treatment did not contain osteoclasts and therefore were excluded from the analysis of osteoclast diameter. In addition, fixation artifacts prevented the determination of osteoblast and osteoclast measures in two samples that were obtained during treatment.
Measurements were carried out using a digitizing table with Osteomeasure software (Osteometrics, Atlanta, GA, USA). Nomenclature and abbreviations follow the recommendations of the American Society for Bone and Mineral Research. (11) Anthropometry and bone densitometry Height and weight measurements were converted to ageand sex-specific Z-scores on the basis of reference data published by the Centers for Disease Control and Prevention. (12) DXA was performed in the anterior-posterior direction at the lumbar spine (L 1 -L 4 ) using a Hologic QDR 2000W or 4500 device (Hologic, Waltham, MA, USA). Areal BMD results were transformed to age-specific Z-scores combining reference data from Salle et al. (13) and data provided by the densitometer manufacturer.
Biochemical measurements
Serum total calcium, phosphate, alkaline phosphatase (ALP) activity, serum PTH concentration (fragment 39-84), serum 25-hydroxyvitamin D [25(OH)D] and osteoclastspecific TRACP activity were measured using standard methods as previously described. (14) Urinary creatinine concentration was quantified colorimetrically. The bone resorption marker urinary cross-linked N-telopeptide of type I collagen (NTX) was quantified by ELISA (Osteomark; Ostex, Seattle, WA, USA) on the second void sample of the morning. Patients were fasting at the time of blood and urine sampling.
Statistical analysis
Variables were tested for normal distribution using the Kolmogorov-Smirnov test. Normally distributed data were expressed as mean and SD. Longitudinal differences were tested for significance using Student's paired t-test or the Wilcoxon test, as appropriate. Differences in samples with and without LOcs were tested with unpaired t-test or Mann-Whitney U-test, as appropriate. The x 2 test was used to evaluate differences in frequency of LOcs between the types of OI and different genetic mutations. Associations are given as Pearson correlation or Spearman rank correlation, as appropriate. All tests were two-tailed, and throughout the study, p < 0.05 was considered significant.
RESULTS
Before pamidronate treatment, LOcs were present in 6 of the 44 (14%) iliac bone specimens. Histomorphometric results of bone structure, formation, and resorption were similar in pretreatment samples with LOcs and in those without LOcs. For example, bone volume per tissue volume was 10.0 ± 2.4% (SD) in samples with LOcs and 8.9 ± 5.0%) in those without (p = 0.6).
After an average of 2.3 yr of pamidronate treatment, LOcs were present in the bone samples of 23 (52%) patients, a significant increase compared with the pretreatment prevalence of LOcs (p < 0.001 by x 2 test; Fig. 1A ). Among the six patients whose pretreatment samples had contained LOcs, only one had detectable LOcs also in the specimen obtained during pamidronate treatment. Some LOcs appeared to be detached from the bone surface (Fig.  1B) , but overall, the percentage of osteoclasts with no visible attachment to a bone surface was similar before and after pamidronate treatment (Table 1) .
Even in samples that contained LOcs, the majority of osteoclasts were of normal size. Therefore, pamidronate treatment was associated with an only modest increase in between-sample averages for osteoclast diameter (18%) and for the number of visible nuclei per osteoclast (43%; Table 1 ). During pamidronate treatment, serum levels of TRACP were associated with osteoclast number (r = 0.35, p = 0.01) but not with average osteoclast diameter (r = 0.07, p = 0.52).
A comparison between iliac bone samples with and without LOcs during pamidronate treatment showed that average core width was higher when LOcs were present ( Table 2 ). The two groups of samples had similar cortical width, but cancellous bone volume per tissue volume was two thirds higher in specimens with LOcs. The higher bone volume per tissue volume in the LOc group was caused by a larger increase in the amount of cancellous bone volume during treatment and reflected a higher trabecular number and a trend toward thicker trabeculae. Parameters of cancellous bone formation were similar between groups.
Even though osteoclast number and surface were higher in samples with LOcs, there was no group difference in eroded surface per bone surface.
The prevalence of LOcs during pamidronate treatment was not associated with OI type and did not depend on whether the disease-causing gene was located in either the COL1A1 or the COL1A2 gene or whether the mutation affected a glycine residue (Table 3) . Patients with LOc-positive bone samples had similar age, duration of pamidronate treatment, height, and weight Z-scores as patients with LOc-negative samples (Table 3) . Similarly, the two patient groups did not differ with regard to lumbar spine areal BMD, serum levels of TRACP, 25(OH)D, PTH, ALP, calcium, or phosphate and urinary NTX/creatinine ratios. There were also no significant group differences in the changes that occurred in these measures during pamidronate treatment (data not shown).
DISCUSSION
This study confirmed previous observations that intravenous pamidronate of young OI patients is associated with a high incidence of abnormally sized osteoclasts. More than one half of the iliac bone samples that were obtained after 2-4 yr of treatment contained at least one LOc, defined as osteoclasts with a diameter >50 mm. Following up on the hypothesis that the presence of LOcs is indicative of toxicity, we compared results in patients with LOc-positive iliac bone samples to those of patients with LOc-negative samples. Importantly, LOcs did not seem to be associated with undesired drug effects. The bone tissue level analysis showed that bone specimens containing LOcs were larger (i.e., had greater core width) and had a more pronounced increase in cancellous bone volume during pamidronate treatment than samples that did not have LOcs. What to make of this constellation of results?
Iliac bone biopsies were obtained at a site located 2 cm posterior of the anterior superior spine. This location is close to the superior growth plate of the iliac bone, resembling thus the metaphysis of a long bone. (15) An iliac bone specimen that is obtained at this site in a growing child contains bone tissue that was created only recently by endochondral ossification. Pamidronate treatment seems to interact with the endochondral ossification process by inhibiting the resorption of newly created trabeculae, thus leading to a higher trabecular number. (1, 8) Bone samples with LOcs had higher cancellous bone volume and higher trabecular number, suggesting that pamidronate had interacted more strongly with endochondral ossification in these samples.
It is our (unpublished) observation that iliac bone at the site of biopsy in growing OI patients resembles a long-bone metaphysis also in that the outer bone dimensions (i.e., core width) decrease with increasing distance from the growth plate. This indicates the presence of ''metaphyseal inwaisting'' caused by periosteal bone resorption, a process that is inhibited by pamidronate treatment. (16) A larger core width in samples containing LOc thus could be a sign of decreased periosteal bone resorption. Thus, both the higher cancellous bone volume and the higher core width in samples containing LOc could be interpreted as a sign of greater sensitivity to the antiresorptive action of pamidronate.
Even though osteoclast number and surface were higher in LOc-positive than in LOc-negative samples, we found no difference in another histomorphometric marker of bone resorption, eroded surface. Similarly, levels of the urinary bone resorption marker N-telopeptide of collagen type I were similar between these two groups. These observations are in accordance with the hypothesis that LOc represent functionally impaired osteoclasts, which thus contribute to increase histomorphometric osteoclast parameters but not functional measures of bone resorption.
All LOc-positive samples also harbored osteoclasts of normal size. This apparent heterogeneity in the pamidronate effect on osteoclast morphology may be surprising. However, it should be noted that, in this study, the biopsy samples were obtained 4 mo after the last pamidronate infusion. It is therefore possible that at the time point captured in this study, the effect of the pamidronate exposure on average osteoclast morphology was decreasing.
Even though the presence of LOc in iliac bone samples was associated with a higher cancellous bone volume, lumbar spine areal BMD was similar in samples with and without LOcs. This is somewhat surprising, because a generalized difference in the amount of cancellous bone should have an effect on lumbar spine areal BMD, even if this measure is not specific for cancellous bone. It is therefore possible that patients with LOc had higher cancellous bone volume only in localized areas close to the growth plate. This hypothesis could be tested by measuring trabecular BMD in the metaphyseal area of long bones using techniques such as pQCT. However, this methodology was not available for this study.
The observed changes in osteoclast size and number of nuclei per osteoclast are similar to those reported in the metaphyses of growing rats that were exposed to bisphosphonates. (6, 7) It is well established that nitrogen-containing bisphosphonates decrease bone resorption mainly though inhibition of osteoclast function rather than osteoclast apoptosis. (5) These drugs are known to interfere with the osteoclast cytoskeleton, which is the likely reason for the abnormalities in osteoclast morphology during bisphosphonate treatment. (17) Our observations in young OI patients are entirely in accordance with these results from rodent experiments.
In conclusion, this study did not show any indication that LOcs during pamidronate treatment are indicative of toxicity. It seems more likely that the observed abnormalities in osteoclast morphology are part of the mechanism of action of this drug. However, it is possible that the presence of particularly large osteoclasts may indicate increased responsiveness to the action of pamidronate, at least in bone tissue that is located close to growth plates.
